Interview with Attorney Rick Collins: New DEA TRT Law Changes for Telemedicine

The speakers explain that pandemic era telemedicine flexibilities changed how patients accessed clinicians. They focus on testosterone therapy because it involves controlled substance prescribing rules. They describe how federal and state policy adjustments created broader remote access during emergencies. They emphasize that rules can shift again, so clinics must track compliance continuously. They frame the topic as important because many patients rely on telemedicine for ongoing TRT care. They describe the conversation as a careful review meant to avoid misinformation and confusion. They set expectations that the discussion is educational and not personal legal advice.

They discuss the DEA’s role and why controlled substance regulation affects telemedicine workflows. They describe how proposed or updated rules can require in person evaluations in some scenarios. They explain that enforcement risk changes when prescribing happens across state lines or at scale. They note that documentation and good faith medical practice standards become critical in audits. They describe how law enforcement and courts can misunderstand medical nuance in testosterone cases. They reference broader steroid regulation history to explain why scrutiny exists around these topics. They stress that clinics should build processes that are defensible, consistent, and clinically justified.

They encourage viewers to follow updates, because timelines and final rules can evolve after announcements. They suggest that telemedicine programs should prepare for multiple outcomes and compliance pathways. They emphasize that patients should ask providers how visits, labs, and follow ups will be handled. They encourage separating medical decision making from internet shortcuts and aggressive marketing claims. They highlight that responsible care requires both clinical competence and regulatory awareness. They close by inviting future conversations that combine legal and medical perspectives on TRT. Overall, the message is that proactive compliance planning reduces risk for everyone involved.